The acquisition will fold ARN’s patented, branded annatto ingredients, along with other functional ingredients and intellectual property in ARN’s pipeline, into Everwell Health’s expanding functional ingredients platform. The transaction does not include Designs for Health’s DuoQuinol ingredient.
In a statement, Everwell Health shared that the deal vertically integrates ARN’s specialized manufacturing facility, strengthening its healthy-aging portfolio as it continues to invest in nature-based bioactive ingredients.
“Our acquisition of American River Nutrition reinforces our commitment to providing scientifically substantiated ingredients which support consumers in living life to their fullest potential,” said Steve Rosenman, CEO of Everwell Health. “These unique and powerful plant-based ingredients further build upon our vision to deliver ingredients that empower all to look, feel and perform their best.”
Following the divestment, Designs for Health will continue to focus on advancing its core clinical nutrition and integrative health solutions through healthcare practitioners.
The ARN deal marks Everwell Health’s third strategic transaction since it was established by private equity firm RoundTable Healthcare Partners in 2021 with the concurrent acquisition of active nutrition leader Nutrition 21.
In March, Everwell Health also acquired all ingredient assets from Things of that Nature, including the cetylated fatty acid technology behind the Celadrin brand. Backed by nearly a dozen clinical studies, Celadrin has demonstrated efficacy in supporting joint health, flexibility, and comfort.
Founded in 1998 by Dr. Barrie Tan, ARN is known for its scientific advancements related to Bixa orellana, a tropically-grown plant commonly known as annatto. Its product line includes DeltaGold—the only tocopherol-free source of tocotrienols, known for their antioxidant benefits—and GG-Gold Geranylgeraniol, a naturally occurring nutrient critical for protein synthesis and the production of key compounds such as testosterone, progesterone, CoQ10, and MK-4 (a form of vitamin K2), all of which decline with age.
Rosenman noted that the expanded ingredient portfolio provides opportunities to innovate new products in key health areas including metabolic, cardiovascular, mitochondrial, muscle, bone and men’s health.
ARN’s manufacturing site and dedicated laboratory will serve as a new innovation center for the company.
Financial details of the transaction were not disclosed.